New Biopharma Company Takes Shape As ACELYRIN Stockholders Approve Merger With Alumis To Develop Therapies For Immune-Mediated Diseases

ACELYRIN, Inc., a late-stage clinical biopharmaceutical company focused on advancing transformative medicines in immunology, announced that its stockholders have approved the company’s proposed merger with Alumis Inc. The approval was given during a special meeting of stockholders held earlier today. As outlined in the amended terms of the merger agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock they hold at the time the transaction is completed. The final results of the stockholder vote will be disclosed in a Form 8-K filing with the U.S. Securities and Exchange Commission. The company expects to complete the merger in the second quarter of 2025.

Mina Kim, Chief Executive Officer of ACELYRIN, said in a statement, “We appreciate our stockholders’ support for our merger with Alumis, reflecting confidence that the merger is the most value-maximizing path forward. We look forward to closing the merger and unlocking the significant value created by bringing together two complementary pipelines and organizations.”